Objective: We aimed to explore the prognostic effect of albumin-bilirubin scores on survival prior to the treatment of patients with gastric cancer with de-novo liver metastasis. Material and Methods: Retrospective screening was conducted on 203 patients who were followed up in our clinic. Two different models have been developed to compare the effect of albumin and bilirubin alone based on the albumin- bilirubin score. Albumin and bilirubin values in Model 1 and albumin-bilirubin grade in Model 2 were included in multivariate analysis. Results: Median age of the patients was 63, and 78.8% of the study population was male. There were 57 (28.1%) patients in the albumin-bilirubin grade 1 group, 95 (46.8%) patients inthe albumin-bilirubin grade 2 group, whereas, 51 (25.1%) patients in the albumin-bilirubin grade 3 group. Median progression-free survival accordingto albumin-bilirubin grades 1-2-3 was8.9 (6.1-11.6) months, 4.2 (2.8-5.5) months, and 0.9 (0.7-1.2) months, respectively (p<0.01). In univariate analysis, poor prognostic effects of high albumin-bilirubin grade were reflected in bothprogression-free survival and overall survival. Multivariate analyzes revealed that in model 1; albumin <3.5 gr/dL and bilirubin >1.2 gr/dL values were prognostic for both progression-free survival and overall survival. In model 2, albumin-bilirubin grade was an independent prognostic factor for progression-free survival and overall survival. {[H 3.45 (1.98-6.02)] in progression-free survival and [H 4.41 (2.45-7.93)] in overall survival for albumin-bilirubin grade 3}. Conclusion: High albumin-bilirubin score (grade) is much more sensitive as compared to low albumin and high bilirubin values alone in showing poor prognosis on progression-free survival and overall survival in patients with gastric cancer with liver metastasis.